NEW YORK (AP) – Pfizer Inc. announced that European Union regulators are reviewing filings for two of its cancer drug candidates.
European Medicines Agency accepted Pfizer’s market application for crizotinib as a treatment for lung cancer, and for bosutinib as a treatment for chronic myeloid leukemia. Pfizer did not say how long it expects the reviews to take.
The two drugs are important parts of Pfizer’s development pipeline. That’s particularly true of crizotinib, a twice-a-day pill that is intended for lung cancer patients whose tumors have a genetic rearrangement of an enzyme that stimulates growth and survival of those cancer cells. It is intended to treat advanced non-small cell lung cancer, which is diagnosed in about 50,000 people worldwide every year. Analysts believe the drug could bring Pfizer billions of dollars in annual revenue.
Date: August 17, 2011
Source: Associated Press
Filed Under: Drug Discovery